National Institute for Health and Care Excellence Releases Medtech Innovation Briefing on the Ekso GT Robotic Exoskeleton
January 24 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, announced today the release by the National Institute
for Health and Care Excellence (NICE) of a Medtech Innovation
Briefing (MIB) on the Ekso GT robotic exoskeleton. The MIB
highlights the innovative aspect of Ekso Bionics’ proprietary
SmartAssist software, which differentiates the Ekso GT from other
available wearable exoskeletons. The MIB notes that
SmartAssist technology allows physiotherapists to strategically
target aspects of a patient's gait by providing different amounts
of support to each leg, effectively personalizing the treatment for
each patient’s specific needs. Ekso Bionics is the first
exoskeleton company to be selected for a MIB by NICE.
NICE is a non-departmental public body of
the Department of Health in the UK that assess the
clinical and cost effectiveness of health technologies to ensure
that all British National Health System (NHS) patients have
equitable access to the most clinically - and cost-effective -
treatments. MIBs, which are written after an evaluation
process, complement existing NICE guidance by providing objective
information on new and novel medical technologies as an aid to
local decision-making by clinicians. The information provided in
the MIB includes a description of the technology, how it is used
and its potential role in the treatment pathway.
“The NHS in the United Kingdom is highly respected and is looked
upon as a reference by many neighboring countries. We are
honored that NICE chose the Ekso GT as the first exoskeleton to be
the subject of a Medtech Innovation Briefing,” stated Thomas Looby,
chief executive officer of Ekso Bionics. “We are thrilled with
the findings and the support of the MIB and are optimistic about
the impact it can have on the momentum for Ekso Bionics in
Europe.”
The MIB authors conducted a systematic review of existing
evidence on multiple patient groups and noted that, while the
evidence base was still limited, results indicated enhancement in
walking speed and distance for patients who use the Ekso GT as a
rehabilitation tool. British specialist commentators who have
used the device noted in the MIB that Ekso GT helps patients with
incomplete spinal cord injuries improve mobility more quickly by
providing a means for repetitive controlled practice and also noted
that the capability for Ekso’s SmartAssist software to apply
different power to each leg might be particularly useful for stroke
patients. The MIB also points out that there were
psychological benefits associated with users being able to stand
and walk, which in turn could have a positive effect on their
overall health.
The MIB report can be found at:
https://www.nice.org.uk/advice/mib93.
About Ekso Bionics® Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first exoskeleton cleared by
the FDA for use with stroke and spinal cord injuries from
L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as
SmartAssist outside the U.S.) software is the only exoskeleton
available for rehabilitation institutions that can provide adaptive
amounts of power to either side of the patient’s body, challenging
the patient as they progress through their continuum of care. The
suit’s patented technology provides the ability to mobilize
patients earlier, more frequently and with a greater number of high
intensity steps. To date, this device has helped patients take more
than 55 million steps in over 120 rehabilitation institutions
around the world.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) estimates or
projection of financial results, financial condition, capital
expenditures, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, changes resulting from the Company’s
finalization of its financial statements for and as of the period
and year ended December 31, 2016, information or new changes in
facts or circumstances that may occur prior to the filing of the
Company’s Annual Report on Form 10-K that are required to be
included therein, the Company's inability to obtain adequate
financing to fund the Company's operations and necessary to develop
or enhance our technology, the significant length of time and
resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024